Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 2
  • Print publication year: 2013
  • Online publication date: August 2013

Chapter 13 - Impulse control disorders and related behaviors

from Section 3 - Specific neuropsychiatric disorders

Related content

Powered by UNSILO

References

1. HoldenC.“Behavioral” addictions: do they exist?Science 2001; 294: 980–2.
2. DagherA, RobbinsTW.Personality, addiction, dopamine: insights from Parkinson's disease. Neuron 2009; 61: 502–10.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000.
4. AntoniniA, SiriC, SantangeloG, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov Disord 2011; 26: 464–8.
5. PietrzakRH, MorascoBJ, BlancoC, GrantBF, PetryNM.Gambling level and psychiatric and medical disorders in older adults: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Am J Geriatr Psychiatry 2007; 15: 301–13.
6. StuckiS, Rihs-MiddelM.Prevalence of adult problem and pathological gambling between 2000 and 2005: an update. J Gambl Stud 2008; 23: 245–57.
7. VolbergRA, Nysse-CarrisKL, GersteinDR. 2006 California Problem Gambling Prevalence Survey. Chicago, IL: National Opinion Research Center at the University of Chicago; 2006.
8. ShafferHJ, HallMN, VanderJ.Estimating the prevalence of disordered gambling behavior in the United States and Canada: a research synthesis. Am J Public Health 1999; 89: 1369–76.
9. BlackDW.A review of compulsive buying disorder. World Psychiatry 2007; 6: 14–8.
10. LilenfeldLR, RinghamR, KalarchianMA, MarcusMD.A family history study of binge-eating disorder. Compr Psychiatry 2008; 49: 247–54.
11. ColemanE.Is your patient suffering from compulsive sexual behavior?Psychiatr Ann 1992; 22: 320–5.
12. GiladiN, WeitzmanN, SchreiberS, ShabtaiH, PeretzC.New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson's disease: the role of dopamine agonist treatment and age at motor symptoms onset. J Psychopharmacol 2007; 21: 501–6.
13. AvanziM, BarattiM, CabriniS, et al. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006; 21: 2068–72.
14. de ChazeronI, LlorcaP-M, Chereau-BoudetI, et al. Hypersexuality and pathological gambling in Parkinson's disease: a cross-sectional case-control study. Mov Disord 2011; 26: 2127–30.
15. OndoWG, LaiD.Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism Relat Disord 2008; 14: 28–32.
16. WicksP, MacPheeGJA.Pathological gambling amongst Parkinson's disease and ALS patients in an online community (PatientsLikeMe.com). Mov Disord 2009; 24: 1085–8.
17. Driver-DunckleyE, SamantaJ, StacyM.Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 2003; 61: 422–3.
18. VoonV, FoxSH.Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 2007; 64: 1089–96.
19. WeintraubD.Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64 (Suppl 2): S93–S100.
20. LuC, BharmalA, SuchowerskyO.Gambling and Parkinson's disease. Arch Neurol 2006; 63: 298.
21. GrossetKA, MacpheeG, PalG, et al. Problematic gambling on dopamine agonists: not such a rarity. Mov Disord 2006; 21: 2206–8.
22. PontoneG, WilliamsJR, BassettSS, MarshL.Clinical features associated with impulse control disorders in Parkinson disease. Neurology 2006; 67: 1258–61.
23. GiovannoniG, O'SullivanJD, TurnerK, MansonAJ, LeesAJL.Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423–8.
24. NirenbergMJ, WatersC.Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006; 21: 524–9.
25. WeintraubD, KoesterJ, PotenzaMN, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589–95.
26. LeeJY, KimJM, KimJW, et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010; 16: 202–7.
27. WeintraubD, SohrM, PotenzaMN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol 2010; 68: 963–8.
28. VoonV, HassanK, ZurowskiM, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006; 67: 1254–7.
29. SteevesTDL, MiyasakiJ, ZurowskiM, et al. Increased striatal dopamine release in parkinsonian patients with pathological gambling: a 11C raclopride PET study. Brain 2009; 132: 1376–85.
30. CeravoloR, FrosiniD, RossiC, BonuccelliU.Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord 2009; 155: S111–15.
31. BjarkamCR, SørensenJC.Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson's disease. Biol Psychiatry 2004; 56: 213–6.
32. LevinBE, KatzenHL.Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. In WeinerWJ, LangAE, eds., Behavioral Neurology of Movement Disorders. New York, NY: Raven Press; 1995. pp. 85–95.
33. GreenJ, McDonaldWM, VitekJL, et al. Cognitive impairments in advanced PD without dementia. Neurology 2002; 59: 1320–4.
34. DuboisB, PillonB.Cognitive deficits in Parkinson's disease. J Neurol 1997; 244: 2–8.
35. BrandM, LabuddaK, KalbeE, et al. Decision-making impairments in patients with Parkinson's disease. Behav Neurol 2004; 15: 77–85.
36. BodiN, KeriS, NagyH, et al. Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009; 132: 2385–95.
37. FrankMJ, SamantaJ, MoustafaAA, ShermanSJ.Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. Science 2007; 318: 1309–12.
38. GerlachM, DoubleK, ArzbergerT, et al. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 2003; 110: 1119–27.
39. SokoloffP, GirosB, MartresMP, BouthenetML, SchwartzJC.Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990; 347: 146–51.
40. HolmanAJ.Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. J Gambl Stud 2009; 25: 425–31.
41. DjamshidianA, JhaA, O'SullivanSS, et al. Risk and learning in impulsive and nonimpulsive patients with Parkinson's disease. Mov Disord 2010; 25: 2203–10.
42. VitaleC, SantangeloG, TrojanoL, et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson's disease. Mov Disord 2011; 26: 830–6.
43. SantangeloG, VitaleC, TrojanoL, et al. Cognitive dysfunctions and pathological gambling in patients with Parkinson's disease. Mov Disord 2009; 24: 899–905.
44. DjamshidianA, O'SullivanSS, LeesA, AverbeckBB.Stroop test performance in impulsive and non impulsive patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17: 212–14.
45. CoolsR.Dopaminergic modulation of cognitive function: implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1–23.
46. CoolsR, AltamiranoL, D'EspositoM.Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006; 44: 1663–73.
47. VoonV, ReynoldsB, BrezingC, et al. Impulsive choice and response in dopamine agonist-related impulse control behaviors. Psychopharmacology (Berl) 2010; 207: 645–59.
48. HousdenCR, O'SullivanSS, JoyceEM, LeesAJ, RoiserJP.Intact reward learning but elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum behaviors. Neuropsychopharmacology 2010; 35: 2155–64.
49. DjamshidianA, O'SullivanSS, WittmannBC, LeesAJ, AverbeckBB.Novelty seeking behaviour in Parkinson's disease. Neuropsychologia 2011; 49: 2483–8.
50. ClaassenDO, van den WildenbergWP, RidderinkhofKR, et al. The risky business of dopamine agonists in Parkinson's disease and impulse control disorders. Behav Neurosci 2011; 125: 492–500.
51. O'SullivanSS, WuK, PolitisM, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain 2011; 134: 969–78.
52. CiliaR, SiriC, MarottaG, et al. Functional abnormalities underlying pathological gambling in Parkinson disease. Arch Neurol 2008; 65: 1604–11.
53. VoonV, PessiglioneM, BrezingC, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010; 65: 135–42.
54. RaoH, MamikonyanE, DetreJA, et al. Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. Mov Disord 2010; 25: 1660–9.
55. FrosiniD, PesaresiI, CosottiniM, et al. Parkinson's disease and pathological gambling: results from a functional MRI study. Mov Disord 2010; 25: 2449–53.
56. CiliaR, KoJH, ChoSS, et al. Reduced dopamine transporter density in the ventral striatum of patients with Parkinson's disease and pathological gambling. Neurobiol Dis 2010; 39: 98–104.
57. CiliaR, ChoSS, Van EimerenT, et al. Pathological gambling in patients with Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. Mov Disord 2011; 26: 225–33.
58. Rodriguez-OrozMC, Lopez-AzcarateJ, Garcia-GarciaD, et al. Involvement of the subthalamic nucleus in impulse control disorders associated with Parkinson's disease. Brain 2011; 134: 36–49.
59. LeeJY, LeeEK, ParkSS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009; 24: 1803–10.
60. DjamshidianA, O'SullivanSS, PapadopoulosA, et al. Salivary cortisol levels in Parkinson's disease and its correlation to risk behaviour. J Neurol Neurosurg Psychiatry 2011; 82: 1107–11.
61. WeintraubD, StewartS, SheaJA, et al. Validation of the Questionnaire for Impulsive-Compulsive Behaviors in Parkinson's Disease (QUIP). Mov Disord 2009; 24: 1461–7.
62. VoonV.Repetition, repetition, and repetition: compulsive and punding behaviors in Parkinson's disease. Mov Disord 2004; 19: 367–70.
63. VoonV, FernagutP-O, BaunezC, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140–9.
64. EvansAH, StrafellaAP, WeintraubD, StacyM.Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561–70.
65. WeintraubD, SiderowfAD, PotenzaMN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969–73.
66. LejoyeuxM, TassainV, SolomonJ, AdèsJ.Study of compulsive buying in depressed patients. J Clin Psychiatry 1997; 58: 169–73.
67. FisherSE.Gambling and Problem Gambling Among Casino Patrons. Report to the British Casino Industry Consortium; 1996.
68. ChristensonGA, FaberRJ, deZwaanM.Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994; 55: 5–11.
69. WeintraubD, MamikonyanE, PapayK, et al. Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale. Mov Disord 2012; 27: 242–7.
70. CabriniS, BarattiM, BonfaF, et al. Preliminary evaluation of the DDS-PC inventory: a new tool to assess impulsive–compulsive behaviours associated to dopamine replacement therapy in Parkinson's disease. Neurol Sci 2009; 30: 307–13.
71. GoetzCG, TilleyBC, ShaftmanSR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129–70.
72. DoddML, KlosKJ, BowerJH, et al. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005; 62: 1–5.
73. MamikonyanE, SiderowfAD, DudaJE, et al. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord 2008; 23: 75–80.
74. MacPheeGJA, CopelandC.Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study. Mov Disord 2009; 24: 2430–1.
75. RabinakCA, NirenbergMJ.Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58–63.
76. ArdouinC, VoonV, WorbeY, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006; 21: 1941–6.
77. SmedingHMM, GoudriaanAE, FonckeEMJ, et al. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease. J Neurol Neurosurg Psychiatry 2007; 78: 517–19.
78. BermejoPE, Ruiz-HueteC, AncionesB.Zonisamide in managing impulse control disorders in Parkinson's disease. J Neurol 2010; 257: 5603–7.
79. SevincokL, AkogluA, AkyolA.Quetiapine in a case with Parkinson disease and pathological gambling [letter]. J Clin Psychopharmacol 2007; 27: 107–8.
80. RotondoA, BoscoD, PlastinoM, ConsoliA, BoscoF.Clozapine for medication-related pathological gambling in Parkinson disease [letter to the editor]. Mov Disord 2010; 25: 1994–5.
81. KlosKJ, BowerJH, JosephsKA, MatsumotoJY, AhlskogJE.Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 2005; 11: 381–6.
82. BenincasaD, PellicanoC, FanciulliA, PontieriFE.Bupropion abates dopamine agonist-mediated compulsive behaviors in Parkinson's disease. Mov Disord 2011; 26: 355–6.
83. GrantJE, PotenzaMN, HollanderE, et al. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry 2006; 163: 303–12.
84. KimSW, GrantJE, AdsonDE, ShinYC.Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 2001; 49: 914–21.
85. ThomasA, BonanniL, GambiF, Di IorioA, OnofrjM.Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol 2010; 68: 400–4.
86. HodginsDC, PetryNM.Cognitive and behavioral treatments. In GrantJE, PotenzaMN, eds., Pathological Gambling: a Clinical Guide to Treatment. Washington, DC: American Psychiatric Press; 2004. pp. 169–88.
87. EvansAH, KatzenschlagerR, PaviourD, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004; 19: 397–405.
88. O'SullivanSS, DjamshidianA, EvansAH, et al. Excessive hoarding in Parkinson's disease. Mov Disord 2010; 25: 1026–33.
89. FriedmanJH.Punding on levodopa. Biol Psychiatry 1994; 36: 350–1.
90. AarslandD, EhrtU, RektorovaI.Cognitive and psychiatric disturbances in Parkinson's disease. Aging Health 2011; 7: 123–42.
91. SpencerAH, RickardsH, FasanoA, CavannaAE.The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord 2011; 26: 578–86.
92. MiyasakiJ, HassanKL, LangAE, VoonV.Punding prevalence in Parkinson's disease. Mov Disord 2007; 22: 1179–81.
93. LawrenceAJ, BlackwellAD, BarkerRA, et al. Predictors of punding in Parkinson's disease: results from a questionnaire survey. Mov Disord 2007; 22: 2339–45.
94. Silveira-MoriyamaL, EvansAH, KatzenschlagerR, LeesAJ.Punding and dyskinesias. Mov Disord 2006; 21: 2214–17.
95. PezzellaFR, ColosimoC, VanacoreN, et al. Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson's disease. Mov Disord 2005; 20: 77–81.
96. FasanoA, PetrovicI.Insights into pathophysiology of punding reveal possible treatment strategies. Mol Psychiatry 2010; 15: 560–73.
97. GraybielAM, CanalesJJ, Capper-LoupC.Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000; 23: S71–7.
98. FernandezHH, FriedmanJH.Punding on L-dopa. Mov Disord 1999; 14: 836–8.
99. MiwaH, MoritaS, NakanishiI, KondoT.Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10: 177–80.
100. KashiharaK, ImamuraT.Amantadine may reverse punding in Parkinson's disease-observation in a patient. Mov Disord 2008; 23: 129–30.
101. LimS-Y, O'SullivanSS, KotschetK, et al. Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease. J Clin Neurosci 2009; 16: 1148–52.
102. EvansAH, LawrenceAD, PottsJ, AppelS, LeesAJ.Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65: 1570–4.
103. EvansAH, PaveseN, LawrenceAD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852–8.
104. RobinsonTE, BerridgeKC.The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18: 247–91.
105. PezzellaFR, Di RezzeS, ChianeseM, et al. Hedonistic homeostatic dysregulation in Parkinson's disease: a short screening questionnaire. Neurol Sci 2003; 24: 205–6.